InvestSMART

Immutep Limited (ASX: IMM) - Announcements

- Current share price for IMM : $0.034

ASX company news and announcements for Immutep Limited (IMM) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Immutep Limited (IMM) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Immutep Limited (IMM), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Immutep Limited (IMM)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$50 Excellent Overall Survival in Head & Neck Cancer Patients 5 May 2025 8:22AM $0.270 $0.034 fallen by 87.41%
$50 Change in substantial holding 1 May 2025 4:36PM $0.260 $0.034 fallen by 86.92%
$50 Immutep Quarterly Activities Report and Appendix 4C 29 Apr 2025 9:02AM $0.260 $0.034 fallen by 86.92%
$50 Immutep Investor Update 23 Apr 2025 10:24AM $0.248 $0.034 fallen by 86.26%
$50 Change in substantial holding 11 Apr 2025 8:20AM $0.240 $0.034 fallen by 85.83%
$50 Change of Director's Interest Notice - M Voigt 8 Apr 2025 3:32PM $0.245 $0.034 fallen by 86.12%
$50 Change of Director's Interest Notice F Triebel 8 Apr 2025 3:31PM $0.245 $0.034 fallen by 86.12%
$50 Application for quotation of securities - IMM 3 Apr 2025 2:31PM $0.253 $0.034 fallen by 86.53%
$50 Immutep to Participate in Upcoming Investor Conferences 2 Apr 2025 8:31AM $0.280 $0.034 fallen by 87.86%
$50 First patient dosed in phase 3 TACTI-004 lung cancer trial 25 Mar 2025 8:38AM $0.285 $0.034 fallen by 88.07%
$50 TACTI-004 trial in progress poster to be presented at ELCC 20 Mar 2025 10:29AM $0.303 $0.034 fallen by 88.76%
$50 Half Yearly Report and Accounts 26 Feb 2025 6:58PM $0.305 $0.034 fallen by 88.85%
$50 Notification of cessation of securities - IMM 6 Feb 2025 6:03PM $0.330 $0.034 fallen by 89.70%
$50 Immutep Corporate Presentation 5 Feb 2025 11:37AM $0.328 $0.034 fallen by 89.62%
$50 Immutep Quarterly Activities Report and Appendix 4C 31 Jan 2025 8:27AM $0.350 $0.034 fallen by 90.29%
$50 Enrolment completed for Ph II trial in Soft Tissue Sarcoma 22 Jan 2025 9:02AM $0.320 $0.034 fallen by 89.38%
$50 Patient Enrolment Completed for INSIGHT-003 6 Jan 2025 8:55AM $0.360 $0.034 fallen by 90.56%
$50 Notification of cessation of securities - IMM 17 Dec 2024 5:21PM $0.340 $0.034 fallen by 90%
$50 Immutep announces initial safety data from IMP761 phase 1 17 Dec 2024 8:20AM $0.340 $0.034 fallen by 90%
$50 Publication Detailing How Human LAG-3 Binds to MHC Class II 16 Dec 2024 8:26AM $0.365 $0.034 fallen by 90.68%
$50 Application for quotation of securities - IMM 13 Dec 2024 12:09PM $0.370 $0.034 fallen by 90.81%
$50 Immutep Reports Promising New Data in Head and Neck Cancer 12 Dec 2024 9:02AM $0.355 $0.034 fallen by 90.42%
$50 Change of Director's Interest Notice - L Boyce 10 Dec 2024 2:49PM $0.335 $0.034 fallen by 89.85%
$50 Change of Director's Interest Notice - R Howard 10 Dec 2024 2:46PM $0.335 $0.034 fallen by 89.85%
$50 Change of Director's Interest Notice - F Triebel 10 Dec 2024 2:45PM $0.335 $0.034 fallen by 89.85%

101 - 125 of 780 results

Page 5 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.